Diabetes, cardiovascular disease and the microcirculation.

Existing Reviews

Please note, new claims can take a short while to show up.

No claims yet.

Annotation Summary

Term Occurence Count Dictionary
type 1 diabetes mellitus 1 endocrinologydiseases
type 2 diabetes mellitus 1 endocrinologydiseases
dapagliflozin 1 endocrinologydiseasesdrugs
diabetes mellitus 3 endocrinologydiseases
diabetic retinopathy 1 endocrinologydiseases
hyperinsulinemia 1 endocrinologydiseases
metabolic syndrome 1 endocrinologydiseases
rosiglitazone 1 endocrinologydiseasesdrugs

Graph of close proximity drug and disease terms (within 200 characters).

Note: If this graph is empty, then there are no terms that meet the proximity constraint.

Review

Having read the paper, please pick a pair of statements from the paper to indicate that a drug and disease are related.

Select Drug Character Offset Drug Term Instance
dapagliflozin 20234 microvascular complications. However, unlike empagliflozin and canagliflozin, short term treatment with dapagliflozin reduced retinal capillary flow and stabilised early structural remodelling (in arteriolar wall cross-sectional
rosiglitazone 26371 resulted in a concomitant increase in the CV event rate [[61]]. Interestingly, additional studies with rosiglitazone indicated an increase in the risk of myocardial infarction while it ameliorated the risk of stroke.The
Select Disease Character Offset Disease Term Instance
diabetes mellitus 319 (collection): /2018AbstractCardiovascular disease (CVD) is the leading cause of mortality in people with type 2 diabetes mellitus (T2DM), yet a significant proportion of the disease burden cannot be accounted for by conventional cardiovascular
diabetes mellitus 1255 causalities of the increased prevalence of CVD and hypertension in people with T2DM.BackgroundType 2 diabetes mellitus (T2DM) and hypertension are established risk factors for cardiovascular disease (CVD), and people with
diabetes mellitus 24445 whereas changes in microvascular function occur before microangiopathy [[86]]. In patients with type 1 diabetes mellitus (T1DM), microvascular defects develop several years after diagnosis, probably relative to glycaemic
diabetic retinopathy 24836 manifested from the stage of diagnosis. Therefore, the fact that an increase in microvascular disease ( diabetic retinopathy ) defines a diagnostic cut-off value for HbA1c indicates the presence of early and progressive pathophysiological
hyperinsulinemia 10248 mortality in comparison with patients without diabetes [[27]–[29]]. The lack of association between hyperinsulinemia and insulin resistance in microvascular dysfunction was questioned in the past [[30]] but it is now
metabolic syndrome 16096 direction of causal effect has not been established. Studies assessing nephropathy, atherosclerosis and metabolic syndrome may provide additional evidence to support this.The effect of anti-diabetes drugs on microcirculationThe
type 1 diabetes mellitus 24438 T2DM whereas changes in microvascular function occur before microangiopathy [[86]]. In patients with type 1 diabetes mellitus (T1DM), microvascular defects develop several years after diagnosis, probably relative to glycaemic
type 2 diabetes mellitus 312 (collection): /2018AbstractCardiovascular disease (CVD) is the leading cause of mortality in people with type 2 diabetes mellitus (T2DM), yet a significant proportion of the disease burden cannot be accounted for by conventional cardiovascular

You must be authorized to submit a review.